| Harmony Hospice 6090 S Fort Apache Rd Ste 130, Las Vegas, NV, 89148 | |
| (702) 880-7525 |
News Archive
The liver plays a critical role in human metabolism. As the gatekeeper of the digestive track, this massive organ is responsible for drug breakdown and is therefore the first to be injured due to overdose or misuse. Evaluating this drug-induced liver injury is a critical part of pharmaceutical drug discovery and must be carried out on human liver cells. Regretfully, human liver cells, called hepatocytes, are in scarce supply as they can only be isolated from donated organs.
Cerus Corporation today announced the pricing of an underwritten public offering of 7,368,422 units, with each unit consisting of one share of its common stock and a warrant to purchase 0.5 of a share of its common stock, at a price to the public of $2.85 per unit. The aggregate public offering price of this offering is approximately $21.0 million, and the net proceeds to the Company, after deducting underwriting discounts and commissions, but before legal and other estimated offering expenses, are expected to be approximately $19.7 million.
In the first clinical trial of a vaginal ring combining two antiretroviral (ARV) drugs, researchers from the Microbicide Trials Network (MTN) are collaborating with the International Partnership for Microbicides (IPM) to evaluate whether the ring is safe for use in women.
Gentium S.p.A. announced today interim results from an independent Data Safety Monitoring Board (DSMB) review of the Company's Phase 3 treatment trial of Defibrotide for Severe Veno-Occlusive Disease (VOD).
› Verified 4 days ago
| Name | Harmony Hospice |
|---|---|
| Location | 6090 S Fort Apache Rd Ste 130, Las Vegas, Nevada |
| Hospice ID | 291514 |
| Category | Freestanding Hospice |
| Ownership Type | Other |
| Profit Type | OTHER |
| SSA county code | 010 |
News Archive
The liver plays a critical role in human metabolism. As the gatekeeper of the digestive track, this massive organ is responsible for drug breakdown and is therefore the first to be injured due to overdose or misuse. Evaluating this drug-induced liver injury is a critical part of pharmaceutical drug discovery and must be carried out on human liver cells. Regretfully, human liver cells, called hepatocytes, are in scarce supply as they can only be isolated from donated organs.
Cerus Corporation today announced the pricing of an underwritten public offering of 7,368,422 units, with each unit consisting of one share of its common stock and a warrant to purchase 0.5 of a share of its common stock, at a price to the public of $2.85 per unit. The aggregate public offering price of this offering is approximately $21.0 million, and the net proceeds to the Company, after deducting underwriting discounts and commissions, but before legal and other estimated offering expenses, are expected to be approximately $19.7 million.
In the first clinical trial of a vaginal ring combining two antiretroviral (ARV) drugs, researchers from the Microbicide Trials Network (MTN) are collaborating with the International Partnership for Microbicides (IPM) to evaluate whether the ring is safe for use in women.
Gentium S.p.A. announced today interim results from an independent Data Safety Monitoring Board (DSMB) review of the Company's Phase 3 treatment trial of Defibrotide for Severe Veno-Occlusive Disease (VOD).
› Verified 4 days ago
| NPI Number | 1285789206 |
| Organization Name | Harmony Home Health Services, Llc |
| Address | 1210 S Valley View Blvd Las Vegas, Nevada, 89102 |
| Phone Number | (702)880-7525 |
News Archive
The liver plays a critical role in human metabolism. As the gatekeeper of the digestive track, this massive organ is responsible for drug breakdown and is therefore the first to be injured due to overdose or misuse. Evaluating this drug-induced liver injury is a critical part of pharmaceutical drug discovery and must be carried out on human liver cells. Regretfully, human liver cells, called hepatocytes, are in scarce supply as they can only be isolated from donated organs.
Cerus Corporation today announced the pricing of an underwritten public offering of 7,368,422 units, with each unit consisting of one share of its common stock and a warrant to purchase 0.5 of a share of its common stock, at a price to the public of $2.85 per unit. The aggregate public offering price of this offering is approximately $21.0 million, and the net proceeds to the Company, after deducting underwriting discounts and commissions, but before legal and other estimated offering expenses, are expected to be approximately $19.7 million.
In the first clinical trial of a vaginal ring combining two antiretroviral (ARV) drugs, researchers from the Microbicide Trials Network (MTN) are collaborating with the International Partnership for Microbicides (IPM) to evaluate whether the ring is safe for use in women.
Gentium S.p.A. announced today interim results from an independent Data Safety Monitoring Board (DSMB) review of the Company's Phase 3 treatment trial of Defibrotide for Severe Veno-Occlusive Disease (VOD).
› Verified 4 days ago
| NPI Number | 1457524613 |
| Organization Name | Global Med Hospice Services Llc |
| Address | 1210 S Valley View Blvd Las Vegas, Nevada, 89102 |
| Phone Number | (702)880-7525 |
News Archive
The liver plays a critical role in human metabolism. As the gatekeeper of the digestive track, this massive organ is responsible for drug breakdown and is therefore the first to be injured due to overdose or misuse. Evaluating this drug-induced liver injury is a critical part of pharmaceutical drug discovery and must be carried out on human liver cells. Regretfully, human liver cells, called hepatocytes, are in scarce supply as they can only be isolated from donated organs.
Cerus Corporation today announced the pricing of an underwritten public offering of 7,368,422 units, with each unit consisting of one share of its common stock and a warrant to purchase 0.5 of a share of its common stock, at a price to the public of $2.85 per unit. The aggregate public offering price of this offering is approximately $21.0 million, and the net proceeds to the Company, after deducting underwriting discounts and commissions, but before legal and other estimated offering expenses, are expected to be approximately $19.7 million.
In the first clinical trial of a vaginal ring combining two antiretroviral (ARV) drugs, researchers from the Microbicide Trials Network (MTN) are collaborating with the International Partnership for Microbicides (IPM) to evaluate whether the ring is safe for use in women.
Gentium S.p.A. announced today interim results from an independent Data Safety Monitoring Board (DSMB) review of the Company's Phase 3 treatment trial of Defibrotide for Severe Veno-Occlusive Disease (VOD).
› Verified 4 days ago
| NPI Number | 1548506157 |
| Organization Name | Global Med Hospice Services Llc |
| Address | 6090 S. Fort Apache Road Las Vegas, Nevada, 89148 |
| Phone Number | (702)471-0205 |
News Archive
The liver plays a critical role in human metabolism. As the gatekeeper of the digestive track, this massive organ is responsible for drug breakdown and is therefore the first to be injured due to overdose or misuse. Evaluating this drug-induced liver injury is a critical part of pharmaceutical drug discovery and must be carried out on human liver cells. Regretfully, human liver cells, called hepatocytes, are in scarce supply as they can only be isolated from donated organs.
Cerus Corporation today announced the pricing of an underwritten public offering of 7,368,422 units, with each unit consisting of one share of its common stock and a warrant to purchase 0.5 of a share of its common stock, at a price to the public of $2.85 per unit. The aggregate public offering price of this offering is approximately $21.0 million, and the net proceeds to the Company, after deducting underwriting discounts and commissions, but before legal and other estimated offering expenses, are expected to be approximately $19.7 million.
In the first clinical trial of a vaginal ring combining two antiretroviral (ARV) drugs, researchers from the Microbicide Trials Network (MTN) are collaborating with the International Partnership for Microbicides (IPM) to evaluate whether the ring is safe for use in women.
Gentium S.p.A. announced today interim results from an independent Data Safety Monitoring Board (DSMB) review of the Company's Phase 3 treatment trial of Defibrotide for Severe Veno-Occlusive Disease (VOD).
› Verified 4 days ago
| Quality Measure | Provider Score | National Score |
|---|---|---|
| Patients or caregivers who were asked about treatment preferences like hospitalization and resuscitation at the beginning of hospice care | 99.7 | 98.3 |
| Patients or caregivers who were asked about their beliefs and values at the beginning of hospice care | 98.9 | 93.6 |
| Patients who were checked for pain at the beginning of hospice care | 97.9 | 93.9 |
| Patients who got a timely and thorough pain assessment when pain was identified as a problem | 59.7 | 77.7 |
| Patients who were checked for shortness of breath at the beginning of hospice care | 98.4 | 97.3 |
| Patients who got timely treatment for shortness of breath | 94.6 | 94.6 |
| Patients taking opioid pain medication who were offered care for constipation | 100.0 | 93.3 |
News Archive
The liver plays a critical role in human metabolism. As the gatekeeper of the digestive track, this massive organ is responsible for drug breakdown and is therefore the first to be injured due to overdose or misuse. Evaluating this drug-induced liver injury is a critical part of pharmaceutical drug discovery and must be carried out on human liver cells. Regretfully, human liver cells, called hepatocytes, are in scarce supply as they can only be isolated from donated organs.
Cerus Corporation today announced the pricing of an underwritten public offering of 7,368,422 units, with each unit consisting of one share of its common stock and a warrant to purchase 0.5 of a share of its common stock, at a price to the public of $2.85 per unit. The aggregate public offering price of this offering is approximately $21.0 million, and the net proceeds to the Company, after deducting underwriting discounts and commissions, but before legal and other estimated offering expenses, are expected to be approximately $19.7 million.
In the first clinical trial of a vaginal ring combining two antiretroviral (ARV) drugs, researchers from the Microbicide Trials Network (MTN) are collaborating with the International Partnership for Microbicides (IPM) to evaluate whether the ring is safe for use in women.
Gentium S.p.A. announced today interim results from an independent Data Safety Monitoring Board (DSMB) review of the Company's Phase 3 treatment trial of Defibrotide for Severe Veno-Occlusive Disease (VOD).
› Verified 4 days ago
| Home Health Aides | 0.25 |
| Counselors | 0.1 |
| Homemakers | 0.25 |
| Licensed Practical or Vocational Nurses | 0.25 |
| Medical Social Workers | 0.1 |
| Physicians | 1.35 |
| Registered Nurses | 0.5 |
| Other Personnel | 0.5 |
| Total Employees | 3.3 |
|---|
News Archive
The liver plays a critical role in human metabolism. As the gatekeeper of the digestive track, this massive organ is responsible for drug breakdown and is therefore the first to be injured due to overdose or misuse. Evaluating this drug-induced liver injury is a critical part of pharmaceutical drug discovery and must be carried out on human liver cells. Regretfully, human liver cells, called hepatocytes, are in scarce supply as they can only be isolated from donated organs.
Cerus Corporation today announced the pricing of an underwritten public offering of 7,368,422 units, with each unit consisting of one share of its common stock and a warrant to purchase 0.5 of a share of its common stock, at a price to the public of $2.85 per unit. The aggregate public offering price of this offering is approximately $21.0 million, and the net proceeds to the Company, after deducting underwriting discounts and commissions, but before legal and other estimated offering expenses, are expected to be approximately $19.7 million.
In the first clinical trial of a vaginal ring combining two antiretroviral (ARV) drugs, researchers from the Microbicide Trials Network (MTN) are collaborating with the International Partnership for Microbicides (IPM) to evaluate whether the ring is safe for use in women.
Gentium S.p.A. announced today interim results from an independent Data Safety Monitoring Board (DSMB) review of the Company's Phase 3 treatment trial of Defibrotide for Severe Veno-Occlusive Disease (VOD).
› Verified 4 days ago
| Others | 0.25 |
| Total Volunteers | 0.25 |
|---|
News Archive
The liver plays a critical role in human metabolism. As the gatekeeper of the digestive track, this massive organ is responsible for drug breakdown and is therefore the first to be injured due to overdose or misuse. Evaluating this drug-induced liver injury is a critical part of pharmaceutical drug discovery and must be carried out on human liver cells. Regretfully, human liver cells, called hepatocytes, are in scarce supply as they can only be isolated from donated organs.
Cerus Corporation today announced the pricing of an underwritten public offering of 7,368,422 units, with each unit consisting of one share of its common stock and a warrant to purchase 0.5 of a share of its common stock, at a price to the public of $2.85 per unit. The aggregate public offering price of this offering is approximately $21.0 million, and the net proceeds to the Company, after deducting underwriting discounts and commissions, but before legal and other estimated offering expenses, are expected to be approximately $19.7 million.
In the first clinical trial of a vaginal ring combining two antiretroviral (ARV) drugs, researchers from the Microbicide Trials Network (MTN) are collaborating with the International Partnership for Microbicides (IPM) to evaluate whether the ring is safe for use in women.
Gentium S.p.A. announced today interim results from an independent Data Safety Monitoring Board (DSMB) review of the Company's Phase 3 treatment trial of Defibrotide for Severe Veno-Occlusive Disease (VOD).
› Verified 4 days ago
| Nathan Adelson Hospice Location: 4141 S Swenson Street, Las Vegas, Nevada, 89119 Phone: (702) 880-7525 |
| Southwest Medical Associates Hospice And Palliativ Location: 1701 W Charleston Ste 150, Las Vegas, Nevada, 89102 Phone: (702) 880-7525 |
| Creekside Hospice Location: 3530 E Flamingo Road Suite 285, Las Vegas, Nevada, 89121 Phone: (702) 880-7525 |
| Always Better Care Hospice Location: 6950 W Via Olivero Ste B4, Las Vegas, Nevada, 89117 Phone: (702) 880-7525 |